The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment

被引：6

作者：

van den Heuvel, Lambertus P. ^{[1
,2
,3
]}

van de Kar, Nicole C. A. J. ^{[1
]}

Duineveld, Caroline ^{[4
]}

Sarlea, Andrei ^{[1
]}

van der Velden, Thea J. A. M. ^{[1
]}

Liebrand, Wilhelmus T. B. ^{[1
]}

van Kraaij, Sanne ^{[2
]}

Schjalm, Camilla ^{[5
,6
]}

Bouwmeester, Romy ^{[1
]}

Wetzels, Jack F. M. ^{[4
]}

Mollnes, Tom E. ^{[5
,6
,7
,8
,9
]}

Volokhina, Elena B. ^{[1
,2
]}

机构：

[1] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Dept Pediat Nephrol, Amalia Childrens Hosp,Med Ctr, Nijmegen, Netherlands

[2] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Dept Lab Med, Nijmegen, Netherlands

[3] Univ Hosp Leuven, Dept Pediat, Leuven, Belgium

[4] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept Nephrol, Nijmegen, Netherlands

[5] Oslo Univ Hosp, Dept Immunol, Oslo, Norway

[6] Univ Oslo, Oslo, Norway

[7] Nordland Hosp, Res Lab, Bodo, Norway

[8] Univ Tromso, KG Jebsen TREC, Tromso, Norway

[9] Norwegian Univ Sci & Technol, Ctr Mol Inflammat Res, Trondheim, Norway

来源：

CELLULAR & MOLECULAR IMMUNOLOGY | 2020年 / 17卷 / 06期

关键词：

THERAPY;

D O I：

10.1038/s41423-020-0406-y

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：653 / 655

页数：3

共 50 条

[31] Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan)
Schols, Saskia
Nunn, Miles A.
Mackie, Ian
Weston-Davies, Wynne
Nishimura, Jun-ichi
Kanakura, Yuzuru
Blijlevens, Nicole
Muus, Petra
Langemeijer, Saskia
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (02) : 334 - 337
[32] Properdin is essential for alternative pathway C5 convertase activity and C5b-9 formation
Michels, Marloes
Maas, Rianne
van der Velden, Thea
de Kar, Nicolevan
Volokhina, Elena
van den Heuvel, Bert
MOLECULAR IMMUNOLOGY, 2022, 141 : 207 - 207
[33] HUMAN ALVEOLAR MACROPHAGES SYNTHESIZE THE FUNCTIONAL ALTERNATIVE PATHWAY OF COMPLEMENT AND ACTIVE C5 AND C9 INVITRO
HETLAND, G
JOHNSON, E
AASEBO, U
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1986, 24 (05) : 603 - 608
[34] IMMUNOADSORBENT AFFINITY PURIFICATION OF THE 5TH COMPONENT (C5) OF HUMAN-COMPLEMENT AND DEVELOPMENT OF A HIGHLY SENSITIVE HEMOLYTIC ASSAY
WETSEL, RA
JONES, MA
KOLB, WP
JOURNAL OF IMMUNOLOGICAL METHODS, 1980, 35 (3-4) : 319 - 335
[35] Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity
Mannes, Marco
Dopler, Arthur
Zolk, Oliver
Lang, Sophia J.
Halbgebauer, Rebecca
Hoechsmann, Britta
Skerra, Arne
Braun, Christian K.
Huber-Lang, Markus
Schrezenmeier, Hubert
Schmidt, Christoph Q.
BLOOD, 2021, 137 (04) : 443 - 455
[36] Complement Inhibition at the Level of C3 or C5: Mechanistic Reasons for Ongoing Terminal Pathway Activity
Mannes, M.
Dopler, A.
Zolk, O.
TRANSPLANTATION, 2021, 105 (04) : 679 - 680
[37] Eculizumab, a C5 complement-blocking antibody, abolishes hemolysis and renders hemolytic patients with paroxysmal nocturnal hemoglobinuria (PNH) transfusion independent.
Hillmen, R
Hall, C
Marsh, J
Elebute, D
Mojcik, CF
Rollins, SA
Richards, S
Rother, RP
BLOOD, 2002, 100 (11) : 44A - 44A
[38] COMPLEMENT COMPONENT C5 IS REQUIRED FOR RELEASE OF ALVEOLAR MACROPHAGE-DERIVED NEUTROPHIL CHEMOTACTIC ACTIVITY
ROBBINS, RA
RUSS, WD
THOMAS, KR
RASMUSSEN, JK
KAY, HD
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1987, 135 (03): : 659 - 664
[39] C5 convertase of the alternative pathway of complement - Kinetic analysis of the free and surface-bound forms of the enzyme
Rawal, N
Pangburn, MK
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (27) : 16828 - 16835
[40] C5 convertase of the alternative pathway of complement: Enzymatic properties of the free and surface-bound forms of the enzyme
Rawal, N
Pangburn, MK
MOLECULAR IMMUNOLOGY, 1998, 35 (6-7) : 392 - 392

← 1 2 3 4 5 →